The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.